- Is topical bicalutamide a safer alternative to finasteride? There is no published human trial of topical bicalutamide for hair loss, and no licensed topical product exists, so it cannot be called safer than finasteride — or shown to work at all. Oral finasteride has decades of trial data with a documented side-effect profile, and topical finasteride has a phase III trial behind it.
- Can pyrilutamide be used by both men and women, or only in specific cases? Pyrilutamide (KX-826) is an investigational topical anti-androgen that has been trialled in both men and women, but it is not approved for hair loss anywhere; the company reports that its China Phase III trial in men met its primary endpoint, but the data come from sponsor announcements rather than peer-reviewed journals, and long-term safety is unknown.
- Kintor Pharmaceutical: KX-826, a New Name in Hair Loss Research KX-826 (pyrilutamide) is an experimental topical androgen receptor blocker from Kintor Pharmaceutical. It is not approved as a medicine anywhere; the company reports that its China Phase III trial met its primary endpoint at 24 weeks, but the trial data has been released through corporate announcements rather than peer-reviewed journals and long-term safety is unknown.
- Is clascoterone suitable for both men and women? Clascoterone is not approved for hair loss in either sex — the approved product is a 1% acne cream. The scalp version has completed phase III trials in men with sponsor-reported positive results; in women the only data is a company-reported phase II significant in one subgroup, so use is off-label and investigational for both.
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
extract, clone, and reinsert your own hair cells
